Back to top
more

SolGel Technologies (SLGL)

(Delayed Data from NSDQ)

$13.42 USD

13.42
44,880

+0.42 (3.23%)

Updated Aug 4, 2025 03:58 PM ET

After-Market: $13.40 -0.02 (-0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Generic Drugs

Zacks News

Zacks Equity Research

Personalis (PSNL) Reports Q4 Loss, Tops Revenue Estimates

Personalis (PSNL) delivered earnings and revenue surprises of 8% and 0.06%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates

Supernus (SUPN) delivered earnings and revenue surprises of 44.23% and 12.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

SLGL Gears Up to Report Q4 Earnings: Here's What You Should Know

Sol-Gel's fourth-quarter 2024 earnings are likely to have gained from higher licensing revenues from its partners.

Zacks Equity Research

Is SolGel Technologies (SLGL) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

SolGel Technologies (SLGL) Upgraded to Buy: Here's What You Should Know

SolGel Technologies (SLGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Sol-Gel Technologies Ltd. (SLGL) Reports Q3 Loss, Tops Revenue Estimates

SolGel Technologies (SLGL) delivered earnings and revenue surprises of 92.31% and 99.29%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Taysha Gene Therapies, Inc. (TSHA) Reports Q3 Loss, Lags Revenue Estimates

Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of -12.50% and 4.54%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Paragon 28, Inc. (FNA) Reports Q3 Loss, Tops Revenue Estimates

Paragon 28, Inc. (FNA) delivered earnings and revenue surprises of 6.25% and 2.10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

SolGel Technologies (SLGL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for SolGel Technologies (SLGL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Equity Research

All You Need to Know About SolGel Technologies (SLGL) Rating Upgrade to Strong Buy

SolGel Technologies (SLGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Sol-Gel Technologies Ltd. (SLGL) Surpasses Q2 Earnings and Revenue Estimates

SolGel Technologies (SLGL) delivered earnings and revenue surprises of 135% and 414.98%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates

Cue Biopharma (CUE) delivered earnings and revenue surprises of 31.03% and 137.96%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Tops Q2 Earnings and Revenue Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of 20.51% and 6.49%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bausch Health (BHC) Beats Q2 Earnings and Revenue Estimates

Bausch (BHC) delivered earnings and revenue surprises of 10.11% and 2.97%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates

SolGel Technologies (SLGL) delivered earnings and revenue surprises of -53.33% and 64.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Lags Revenue Estimates

Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of 9.09% and 7.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sharecare, Inc. (SHCR) Reports Q1 Loss, Misses Revenue Estimates

Sharecare (SHCR) delivered earnings and revenue surprises of 0% and 12.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bausch Health (BHC) Q1 Earnings and Revenues Miss Estimates

Bausch (BHC) delivered earnings and revenue surprises of -21.33% and 1.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Generation Bio Co. (GBIO) Reports Q4 Loss, Lags Revenue Estimates

Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -29.27% and 5.64%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates

Supernus (SUPN) delivered earnings and revenue surprises of -95.12% and 6.39%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies

Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies are part of the Zacks Industry Outlook article.

Sundeep Ganoria  headshot

3 Generic Drug Stocks to Watch Amid Improving Market Prospects

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, AMPH and SLGL.

Zacks Equity Research

Sol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue Estimates

Sol-Gel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 15.38% and 61.68%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

Personalis (PSNL) delivered earnings and revenue surprises of 10.71% and 0.29%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Tops Revenue Estimates

Sol-Gel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -86.36% and 51.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?